记者丨 贺佳雯 编辑丨李果 周上祺 2026年3月5日，十四届全国人大四次会议在北京人民大会堂开幕。在"十五五"开局之年的关键 节点，2026年政府工作任务中，医疗健康内容，释放出超越民生保障范畴的信号。 信号一：" 2 4元"的含金量 报告提出，居民医保人均财政补助标准提高24元。这意味着什么？ "新兴"与"支柱"，折射出国家层面对该产业布局的根本性转变。1月17日，在国家医保局召开 的医保药品器械（集采）交易与价格平台支持中国药械"走出去"座谈交流活动上，医保系统人 士也曾和记者表示，接下来会重点搭建平台，推动中国医药器械企业出海。 居民医保由"个人缴费＋财政补助"共同组成。这次补助标准提高，意味着有效减轻居民医保缴 费压力。 首都医科大学一位长期研究医保政策的专家告诉记者："这恰恰说明了我们政策的稳定和量力 而行。"要知道从2003年城乡居民医保制度建立以来，居民医保人均财政补助标准每年都在提 高。财政补助从最初的10元涨至2025年的700元，今年再增至724元。按个人缴费400元计算， 财政补助在人均筹资总额中占比约64%。连续多年的固定动作，意味着政策稳定性支撑人民生 活的稳定性。 据统计，201 ...

Core Insights - Daxing Biopharmaceutical Industry Base has achieved significant milestones, including being recognized as a national-level "Green Industrial Park" and a five-star national new-type industrialization demonstration base, with plans for expansion and development in the biopharmaceutical sector [1][2][8] Group 1: Development Milestones - In 2021, Daxing Biopharmaceutical Industry Base was approved for a 9.1 square kilometer expansion, marking its entry into the trillion-level industrial park category [1] - The base was awarded the title of "Green Industrial Park" in 2022 and has been recognized for its innovative development strategies [1][2] - The construction of the new campus for Capital Medical University commenced in 2023, enhancing the collaborative innovation framework of "medical education, research, and production" [1][8] Group 2: Expansion Projects - The first industrial land project in the southern expansion area, the Ande Medical Health Industry Park, broke ground in February 2025, with a total investment of approximately 300 million yuan [7] - The northern expansion area, covering 5.5 square kilometers, focuses on living and service facilities, with the new campus of Capital Medical University as a key project [8] - During the "14th Five-Year Plan" period, the base completed 12 transactions for industrial land, emphasizing high-standard planning before construction [8] Group 3: Industry Focus and Innovation - The base has established a "3+5" industrial development roadmap, focusing on traditional Chinese medicine, vaccines, and high-end medical devices, while also exploring emerging fields like cell and gene therapy [10][11] - Daxing has become a hub for vaccine production, housing leading companies in the sector, and has transitioned from "following innovation" to "original breakthroughs" [10] - The base is also strengthening its position in high-end medical devices, with advancements in surgical robots and innovative medical implants [11] Group 4: Service and Support for Enterprises - Daxing Biopharmaceutical Industry Base provides comprehensive services for enterprises, including project site selection, business registration, environmental assessments, and policy applications [14] - A one-stop service platform has been established, integrating government services and industry resources, which has facilitated over 26,000 services to enterprises [14] - The base has organized various events to enhance collaboration and visibility for enterprises, leading to successful international market expansions for over 20 companies [15] Group 5: Future Outlook - The base aims to further optimize its industrial system by focusing on the "3+2+N" model, which includes strengthening existing industries and exploring new potential sectors [17] - The "15th Five-Year Plan" emphasizes the development of new productive forces and high-quality economic growth, aligning with Daxing's strategic goals [17] - Daxing Biopharmaceutical Industry Base is committed to continuing its role as a key player in the biopharmaceutical industry, with plans for further expansion and innovation [17]

Core Insights - The 8th China International Import Expo (CIIE) will be held from November 5 to 10, 2025, in Shanghai, featuring participation from 155 countries and regions, with over 4,108 foreign enterprises exhibiting, marking a record exhibition area of over 430,000 square meters [1] - The CIIE has successfully showcased China's vast market potential and commitment to openness, contributing positively to global economic development [1] - The life sciences sector in China is experiencing significant innovation, particularly in precision medicine and biopharmaceuticals, reshaping healthcare services [1] - Illumina, a leader in gene sequencing and chip technology, is participating in the CIIE for the sixth time, focusing on innovative solutions in the medical device and healthcare sector [1] Company Strategy - Illumina is celebrating its 20th anniversary in China, emphasizing its commitment to localization and bringing innovative solutions to the Chinese market [2] - The company aims to enhance local procurement and manufacturing, marking a new phase in its localization strategy [2][3] - Illumina's strategy aligns with China's "14th Five-Year Plan," which promotes high-quality development in the biopharmaceutical industry and emphasizes the importance of local manufacturing and supply chain resilience [3][4] Product Innovations - Illumina introduced two cutting-edge solutions at the CIIE, including the Illumina Protein Prep solution and a new five-base solution, both aimed at advancing drug discovery and precision medicine [8][9] - The NovaSeq 6000Dx-CN-BG, a high-throughput sequencing instrument, has received regulatory approval in China, enhancing its clinical applications in oncology and rare disease detection [6][11] - The new five-base solution addresses limitations in traditional sequencing methods, allowing for simultaneous detection of genetic markers, thus improving efficiency in clinical research [9] Market Positioning - Illumina's localization efforts are supported by strategic partnerships with local companies to strengthen supply chain resilience and enhance local manufacturing capabilities [5][6] - The company is committed to providing innovative solutions that meet international standards, facilitating the integration of Chinese research with global practices [12][13] - Illumina's ongoing investments in R&D, projected at nearly $1 billion for 2024, reflect its dedication to supporting China's life sciences innovation [11][14]

Group 1: Industry Overview - The Hong Kong Trade Development Council (HKTDC) reports that Hong Kong is collaborating with Guangdong and Macau to advance technological innovation in the Greater Bay Area, with biomedicine emerging as a key industry cluster [1] - The number of biomedical companies in Hong Kong has increased significantly from 2,340 in 2013 to 3,020 in 2023, indicating robust growth in the sector [1] - The Guangdong provincial government aims to accelerate the development of the biomedicine industry, targeting a cluster scale exceeding 1 trillion RMB by 2027, up from 664 billion RMB in 2023, representing a 50% increase [1] Group 2: Financial Landscape - As of June 30, 2025, the total market capitalization of the healthcare sector listed in Hong Kong is $441 billion, accounting for approximately 8.1% of the total market capitalization of listed companies in Hong Kong, a threefold increase from $144 billion at the end of 2017 [2] - There are currently 73 biotech companies listed under the 18A regime, having raised a total of $16 billion [2] - Hong Kong's advanced clinical trial capabilities and internationally recognized clinical trial data position it as an ideal location for expanding global biomedicine businesses [2] Group 3: Startup Ecosystem - The number of biotech and health tech startups in Hong Kong has surged from 110 in 2018 to 510 in 2024, increasing their share of total startups from 4% to 11%, outpacing other startup sectors [3] - These startups are involved in various cutting-edge fields, including new drug development, gene editing technology, medical device innovation, and precision medical solutions [3]

Group 1 - The core viewpoint emphasizes the acceleration of the development of China's biopharmaceutical industry, focusing on innovation-driven, long-cycle, and differentiated development to establish a national team in the biopharmaceutical sector [1] - In the first half of 2025, the number of approved innovative drugs in China reached 43, a year-on-year increase of 59%, with domestic innovative drugs accounting for 93% [1] - A complete policy support system has been established since 2021, facilitating the entire process from research and development to market access, clinical trials, payment, and insurance for innovative drugs [2] Group 2 - The total transaction amount for overseas licensing by Chinese pharmaceutical companies reached $51.9 billion in 2024, a 36% increase from the previous year, with the amount exceeding $60.8 billion in the first half of 2025 [2] - The collaboration between 3SBio and Pfizer for a PD-1/VEGF bispecific antibody set a record for the highest upfront payment of $1.25 billion for domestic innovative drug licensing [3] - The partnership between Heng Rui Medicine and GlaxoSmithKline has a potential total value of $12 billion, showcasing the enhanced global competitiveness of Chinese innovative drugs [3] Group 3 - The State-owned Assets Supervision and Administration Commission encourages state-owned enterprises to enhance their influence in the biopharmaceutical sector through mergers, acquisitions, and investments [4] - Domestic pharmaceutical companies are shifting from being technology followers to key contributors in global innovation, with significant advancements in various therapeutic areas [4] - Morgan Stanley predicts that by 2030, innovative drug sales will account for 53% of China's pharmaceutical market, up from 29% in 2023, with a compound annual growth rate of 21% [5]

Report Summary 1. Industry Investment Ratings No industry investment ratings are provided in the report. 2. Core Views - The report presents the market trends and outlooks for various commodities, including precious metals, base metals, energy products, agricultural products, and chemical products. Each commodity's trend is described as high - level shock, small decline, range shock, etc., based on their respective fundamentals and market news [2][4]. 3. Summary by Commodity Precious Metals - **Gold**: Expected to experience high - level shock. Yesterday, the closing price of Shanghai Gold 2510 was 772.68, with a daily decline of 0.31%. Comex Gold 2510 rose by 0.99% to 3392.20. The trend strength is 1 [2][5][6]. - **Silver**: Forecasted to have a small decline. The closing price of Shanghai Silver 2510 was 9042, down 1.57%. The trend strength is - 1 [2][5][6]. Base Metals - **Copper**: Lacks a clear driving force, and the price will fluctuate. The closing price of Shanghai Copper's main contract was 78,630, down 0.30%. The trend strength is 0 [2][12]. - **Zinc**: Will trade in a range. The closing price of Shanghai Zinc's main contract was 22,265, up 0.27%. The trend strength is 0 [2][15]. - **Lead**: Inventory reduction supports the price. The closing price of Shanghai Lead's main contract was 16,725, down 0.59%. The trend strength is 0 [2][18]. - **Tin**: Will trade in a range. The closing price of Shanghai Tin's main contract was 267,840, down 0.09%. The trend strength is - 1 [2][21]. - **Aluminum**: Expected to experience high - level shock. The closing price of Shanghai Aluminum's main contract was 20,535, down 10. The trend strength is 0 [2][26]. - **Nickel**: The fundamentals will cause narrow - range fluctuations, and beware of news - based risks. The closing price of Shanghai Nickel's main contract was 119,930, down 400. The trend strength is 0 [2][28]. - **Stainless Steel**: The steel price will fluctuate due to the game between macro - expectations and reality. The closing price of the stainless - steel main contract was 12,820, down 65. The trend strength is 0 [2][28]. Energy and Chemical Products - **Carbonate Lithium**: The game between reality and expectations intensifies, and the market volatility will increase. The closing price of the 2509 contract was 81,040, down 6,540. The trend strength is 0 [2][34]. - **Industrial Silicon**: Market sentiment is boosted. The Si2511 closing price was 8,390, down 235. The trend strength is 1 [2][37]. - **Polysilicon**: Quotes are rising, and sentiment continues to be boosted. The PS2511 closing price was 51,875, down 385. The trend strength is 1 [2][38]. - **Iron Ore**: Macro - risk appetite has not significantly reversed, and support remains. The trend strength is 1 [2][41]. - **Rebar and Hot - Rolled Coil**: Both will experience wide - range fluctuations. The closing price of RB2510 was 3,132, down 12; HC2510 was 3,402, down 21. The trend strength for both is 0 [2][43][44]. - **Silicon Ferroalloy and Manganese Ferroalloy**: Market sentiment is cold, and both will experience weak - side fluctuations. The closing price of Silicon Ferroalloy 2511 was 5622, down 56; Manganese Ferroalloy 2511 was 5818, down 80. The trend strength for both is - 1 [2][47]. - **Coke and Coking Coal**: Both will experience wide - range fluctuations. The closing price of JM2601 was 1162.5, down 32; J2601 was 1678, down 30.5. The trend strength for both is 0 [2][50]. - **Log**: The price will fluctuate repeatedly. The closing price of the 2509 contract was 805.5, down 0.6%. The trend strength is 0 [2][53]. - **Para - Xylene**: Crude oil rebounds, demand improves, and it is unilaterally strong. The closing price of the PX main contract was 6844, up 1.03%. - **PTA**: Cost provides support, and it is strong in the short - term. The closing price of the PTA main contract was 4778, up 0.93%. - **MEG**: There is an expectation of overseas supply contraction, and it is strong in the short - term. The closing price of the MEG main contract was 4477, up 1.20% [2][57]. Agricultural Products - **Palm Oil**: Fundamentals provide strong support, and go long on macro - pullbacks. - **Soybean Oil**: Driven by US soybeans is insufficient, and it will experience high - level shock consolidation. - **Soybean Meal**: Overnight US soybeans rose slightly, rapeseed meal was weak, and Dalian soybean meal may fluctuate. - **Soybean No.1**: Will experience weak - side fluctuations. - **Corn**: Will operate weakly. - **Sugar**: Will be strong with fluctuations. - **Cotton**: Pay attention to the listing situation of new cotton. - **Egg**: Pay attention to the culling rhythm of old hens. - **Live Pig**: Wait for the end - of - month spot verification. - **Peanut**: Near - term contracts are strong, and far - term contracts are weak [2][4].

1. Report Industry Investment Rating - No relevant content provided 2. Core View of the Report - In 2025, domestic liquidity is expected to remain loose and the market is in a policy window period. More incremental policies may be introduced in the second half of the year to boost the real economy. External risks are gradually easing, with a 90 - day extension of the suspension of Sino - US tariffs and an increased probability of the Fed cutting interest rates in September, which further enhances the attractiveness of RMB assets. The current market is in a resonance period of "policy bottom + capital bottom + valuation bottom", and the market trend is likely to continue, but investors need to adapt to accelerated sector rotation and structural differentiation. The CSI 500 and CSI 1000 indexes, which are dominated by technology - growth stocks, are more offensive with larger fluctuations but may bring higher returns, while the SSE 50 and CSI 300 indexes, which are dominated by dividend blue - chip stocks, are more defensive with smaller fluctuations but relatively weaker price elasticity [2] 3. Summary by Relevant Catalogs 3.1 Stock Index Futures Market - **IF Contracts**: The closing prices of IF contracts for different periods increased, with increases of 49.00, 46.80, 49.60, and 50.80 respectively. The trading volume of the current - month contract was 90137.00, and the open interest increased by 4297.00. The price - to - price spreads between the next - month and current - month contracts changed from - 4.80 to - 8.60 [1] - **IH Contracts**: The closing prices of IH contracts for different periods also rose, with increases of 30.40, 30.60, 29.60, and 29.00 respectively. The trading volume of the current - month contract was 45450.00, and the open interest of the current - month and next - month contracts increased, while that of the next - quarter and far - quarter contracts decreased. The price - to - price spreads between the next - month and current - month contracts changed from 0.20 to 0.00 [1] - **IC Contracts**: The closing prices of IC contracts for different periods increased significantly, with increases of 92.40, 98.00, 94.20, and 103.20 respectively. The trading volume of the current - month contract was 77339.00, and the open interest increased in all periods. The price - to - price spreads between the next - month and current - month contracts changed from - 43.40 to - 37.00 [1] - **IM Contracts**: The closing prices of IM contracts for different periods rose, with increases of 88.60, 93.60, 98.40, and 106.60 respectively. The trading volume of the current - month contract was 196109.00, and the open interest increased in all periods. The price - to - price spreads between the next - month and current - month contracts changed from - 50.80 to - 47.80 [1] 3.2 Stock Index Spot Market - **Index Performance**: The SSE 50 index increased by 1.23%, the CSI 300 index increased by 1.14%, the CSI 500 index increased by 1.09%, and the CSI 1000 index increased by 0.86%. The trading volume and total trading amount of each index showed different degrees of change [1] - **Industry Performance**: Among different industries, the information technology industry had the highest increase of 2.51%, followed by optional consumption (1.36%), raw materials (1.35%), etc., while the public utilities industry had the lowest increase of 0.16% [1] 3.3 Futures - Spot Basis - The basis of different contracts relative to their corresponding spot indexes changed. For example, the basis of the IF current - month contract relative to the CSI 300 index changed from - 7.17 to - 1.40, and the basis of the IH current - month contract relative to the SSE 50 index changed from 2.98 to 4.21 [1] 3.4 Other Domestic and Overseas Indexes - **Domestic Indexes**: The Shanghai Composite Index increased by 1.04%, the Shenzhen Component Index increased by 0.89%, the Small and Medium - sized Board Index increased by 1.38%, and the ChiNext Index increased by 0.23% [1] - **Overseas Indexes**: The Hang Seng Index increased by 0.17%, the Nikkei 225 decreased by 1.51%, the S&P 500 decreased by 0.24%, and the DAX index decreased by 0.60% [1] 3.5 Macro Information - The Ministry of Finance and the State Taxation Administration announced that child - rearing subsidies are exempt from personal income tax starting from January 1, 2025. The new LPR remained unchanged for three consecutive months, with the 1 - year LPR at 3.0% and the over - 5 - year LPR at 3.5%. The Fed's July meeting minutes showed that almost all policymakers supported not cutting interest rates, and there were differences among officials regarding inflation, employment risks, and the impact of tariffs on inflation. Premier Li Qiang emphasized promoting the quality improvement and upgrading of the biomedical industry, and the State Council General Office proposed a classified and hierarchical approach to implement existing PPP projects [2] 3.6 Industry Information - Some platform companies have reported basic information as required, and the tax department will conduct publicity, guidance, and interviews for those that have not. The State Administration for Market Regulation plans to introduce new regulations on anti - monopoly in the public utilities sector. Multiple rural banks in Zhejiang, Guizhou, Jilin and other places have lowered deposit interest rates by 10 - 20 basis points, while many banks have launched large - denomination certificate of deposit products with an annual interest rate of over 2%. In July, the comprehensive inventory coefficient of automobile dealers was 1.35, a 4.9% month - on - month and 10% year - on - year decrease, with the inventory level below the warning line but above the reasonable range [2]